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ABSTRACT 
Tackling the Challenges of Antimalarial Drug Resistance in Nigeria 
Author: Bundo Onwueme 
Advisor: Dr. John Rich 
 
 
 
 
   
 
 This Community Based Master’s Project for the Degree of Master of Public Health is a 
comprehensive work aimed to outline the relationship with antimalarial drug resistance and 
policies in Nigeria.  The purpose of this research is to develop and evaluate the impact of 
antimalarial drug policies on the social welfare and public health needs of the Nigerian people.   
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Introduction 
Malaria is a preventable and treatable infectious disease that affects hundreds of millions 
of people primarily in the developing world.  It is the most important of the parasitic diseases of 
humans with 107 countries and territories having areas at risk of transmission, and containing 
close to 50 percent of the world's population (4).  Malaria is endemic in parts of Asia, Africa, 
Central and South America, Oceania, and certain Caribbean islands. The global scale of the 
problem is heavily confined to Nigeria, as the health of its community and citizens are threatened 
by the sustained suffering and death that the disease causes.  Antimalarials are agents used in the 
treatment of malaria.  Usually, they are classified on the basis of their action against plasmodia at 
different stages in their life cycle in the human.  Over the past decades, antimalarial drug 
resistance has developed.  Antimalarial drug resistance has been defined as the “ability of a 
parasite strain to survive and/or multiply despite the administration and absorption of a drug 
given in doses equal to or higher than those usually recommended but within tolerance of the 
subject” (33). 
 
Hypothesis: Increased antimalarial drug resistance is perpetuated by poor surveillance, improper 
regulation, and ineffective policies.  
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Specific Aims of Study: 
1. To assess the effects of Nigeria’s antibiotic-regulation policies on malaria disease burden.  
2. To evaluate the efficacy and efficiency of current government regulatory techniques, and 
physician regulation oversight with respect to antibiotic resistance. 
3. To identify gaps and limiting factors in current policy implementation guidelines in 
current policies. 
 
Research Design and Methods: 
Specific aims (1-3) above will be addressed through literature based analyses.  These 
include collecting and analyzing data from peer reviewed articles, textbooks, and journals.  We 
searched journals and public domain literature articles on MEDLINE for policy documents that 
contained advanced keyword searches on “antibiotic drug resistance,” “malaria,” “Nigeria,” and, 
“National Drug Policy in Nigeria, the National Agency for Food, Drug Administration & Control 
(NAFDAC).”  Search results were evaluated on their abstract, especially if they included a 
comprehensive scope of criteria that we specified.  Specification parameters to restrict our 
findings included humans, the literature review in English, and relevant publications in the years 
between 1998 and 2009.  The articles we focused on sought to explore and highlight topics 
relevant to national antimalarial drug resistance and control in Nigeria.  We obtained data about 
malaria polices and factors such as behavior, cost, supply, pharmaceutical company regulation, 
physician regulation, and surveillance that influence drug resistance.  In addition to the literature 
review, we also relied on interviews and analyses from agencies and experts with special interest 
in the policy problem (Emmanuel Anteyi, MD (National Hospital, Abuja):, John Idoko MD (Jos 
University Teaching Hospital and AIDS Prevention Initiative Nigeria), Dr M. Etiebet, MD MBA 
(Institute of Human Virology, Abuja; Kenolisa Onwueme MD, PhD Brigham and Women's 
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Hospital, a teaching affiliate of Harvard Medical School) regarding antibiotic practices in 
Nigeria. Our interviews were conducted by telephone, email, and in-person.  Responses to 
survey questions were collected by note-taking and then later annotated and grouped into themes 
pertaining to question, and finally analyzed in comparison with the literature review to derive our 
conclusion.  We used these methods to analyze collected data regarding policy and regulation in 
Nigeria.  Moreover, we hoped to deduce and identify strategies to improve public health needs of 
antimalarial drugs.  These methods were used to obtain the data required to meet the specific 
aims of this literature based study.   
 
Figure 1. Malaria Cycle. Source: www.fda.gov/CbER/blood/malaria071206sk5.gif 
 
Malaria: Background and Significance 
As a health problem, malaria continues to persist in many parts of sub-Saharan Africa 
and South Asia, whereas it has been virtually eliminated in much of the rest of the world.  In sub-
Saharan Africa, about 300 million people suffer acute cases of malaria each year, with one 
million dying at least 70% of who are children or pregnant women (5).  In Nigeria, malaria has 
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threatened the current healthcare of its citizens and presents an urgent challenge to the country.  
Nigeria is a country in Western Africa, bordering between Benin and Cameroon with an 
estimated population of 146,000,000.  See figure 2.  Throughout the country, malaria is 
transmittable 10 months out of the year, from February to December (16). This correlates with 
lower life expectancy and compounds excess morbidity and mortality.  Malaria is caused by 
parasites from the plasmodium family. Their transmission is mediated by the Anopheles 
mosquito vector of which there are some 32 species.  There a four major plasmodium species 
that account for the majority of diseases in humans: plasmodium malariae, plasmodium 
falciparum, plasmodium ovale, plasmodium vivax, with the main parasite as Plasmodium 
falciparum.   
Figure 1 illustrates the different stages of the pathogen’s life cycle. During this process 
malaria parasites destroy red blood cells, interfering with their replenishment, and causing 
anemia in both the acute and chronic forms. When left untreated, malaria can cause numerous 
complications: including kidney failure, anemia, coma, and death, along with the serious threat it 
presents to pregnant women (11).   
 
 
History of Malaria Resurgence 
1940’s-Development of residual 
insecticides and antimalarials after 
WWII gave birth to the idea that 
malaria could be eradicated. 
 
1950’s-Malaria eradication 
programs end because of slow 
progress due to increasing 
insecticide and antimalarial use. 
1970’s-Chloroquine resistance is 
reported 
 
 
 
 
 
Chart 1. History of Malaria resurgence 
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The detection of resistance by proliferation of vector borne parasites occurred in the early 
1970’s (see chart 1), and are attributed to 4 main factors: 1) local environmental conditions 
(temperature, humidity), 2) abundance of vectors and intermediate or reservoir hosts, 3) 
prevalence of the disease-causing pathogen suitably adapted to vectors and human or animal 
host, and 4) resilience behavior and immune status of human populations.  However, in recent 
decades, resistance to certain antimalarials has developed, posing a threat to the immediate 
society where the endemicity is high, and should sound a global alarm at the threat it poses.   
 
Figure 2. Approximate distribution of Malaria Source: WHO/CSR from http://www.who.int/emc 
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Nigeria’s current antimalarial-regulation policies in their present form are failing to 
curtail the disease burden.   
More importantly, we are continually reminded that the global scale of the problem is not 
confined to Nigeria, as  the health of US travelers and relief workers is threatened, thus widening 
the humanitarian aid crisis and damaging efforts for life-saving treatments.   
The sustained suffering and death of individuals dealing with the ills of malaria cannot be 
allowed to continue.  Peddling of fake drugs, combined with the short shelf-life of many 
antimalarials on the market, and the lack of trained officials in the supply-chain and distribution 
pipelines leads to a great deal of improper use, waste, and death. This project initiative will 
require closer collaboration with key government representatives and agencies with special 
interest in the policy problem in order to make better use of resources.  
 
Figure 3. Burden of malaria cases. Source: World Malaria Report 2008. 
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Significance of Problem: Antimalarial Drug Resistance  
Antimalarial drug policy control in Nigeria is based almost exclusively on chemotherapy 
using quinines (QUI), the cheapest antimalarial drug, or its close derivatives.  The two main 
derivatives are chloroquine (CQ) and mefloquine (MQ).  Often, chloroquine is the first line drug 
for uncomplicated Malaria, but mefloquine is more widely used due to emerging chloroquine 
resistance.  Sulphadoxine-pyrimethamine (SP, Fansidar), is the second-line of treatment 
recommended for severe Malaria (16).  Between 1978 and 1988 plasmodium falciparum 
resistance to chloroquine had been reported in all countries of tropical Africa (5).  Malaria 
parasites had developed a genetic mutation preventing chloroquine and quinine absorption, and 
expelling them from the parasite’s body.   This defense mechanism does not allow chloroquine 
and quinine to be effective.   In 1972, a crystalline compound was extracted from the qinghaosu 
plant, known in western countries as “artemisinin” (ACM) to treat malaria, due to the waning 
efficacy of other low-cost drugs and the emergence of drug resistance in Asia (14).  
Administered orally, and with no major side effects or severe toxicity reported, artemisinins have 
been used for the prevention of malaria in pregnancy.  The reasons for the development and 
spread of drug resistance involve the interaction of drug-use patterns, characteristics of the drug 
itself, human host factors, parasite characteristics, sub-standard or fake drugs, and vector related 
environmental factors (14).  See figure 4. The antimalarial drugs (chloroquine, fansidar, 
camouqin) have long been thought of as the most effective remedies to treat malaria because of 
their efficacy, low-cost and availability.  Antimalarials drugs are obtainable with or without 
prescription.  In hospitals, all medication is dispensed only by prescription unlike the case in the 
wider communities where CQ and SP’s can be purchased over the counter (OTC). The 
comparative retail price per dose of these medications was in the order: ACMs > QUI > SP > CQ 
14 
 
(33).   Artemisinins cost about 20 times more than chloroquine, and African countries and their 
citizens cannot afford their higher price tag.  Currently, the practice in Nigeria for recommended 
treatment regimens often do not reflect the current state of antimalarial drug resistance.  In 
theory, recommended treatment regimens should be tailored specifically to a given region based 
on resistance patterns found in that area. However, considerations such as cost, cost-
effectiveness, availability, ease of administration, capabilities of the health care infrastructure 
(i.e. do health care workers have the equipment and training to safely use parenteral routes of 
administration?), perceived efficacy, and perceived safety of the drug (acceptability of the drug 
by the population) must be acknowledged (33).  
 
Figure 4. Factors contributing to antimalarial drug resistance 
 
Surveillance 
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th 
(4).  Although the last century witnessed m
tion 
l Niño 
ore, the deterioration of public health infrastructure, 
contribute to antimalarial resistance. 
Literature review: Nigerian National Drug Policies  
Where malaria prospers most, human societies have prospered least. The global 
distribution of per-capita gross domestic product shows a striking correlation between malaria 
and poverty, but also shows that malaria-endemic countries have lower rates of economic grow
any successful programs at country level to eliminate 
the malaria parasite, the world is now facing a rapidly increasing malaria disease burden (5).  
Antimalarial drug resistance has been attributed to several causes including popula
movements into malaria-endemic regions, changing agricultural practices (e.g. the building of 
dams and irrigation schemes), deforestation, weakening of public health systems in poor 
countries, and more speculatively, long-term climate changes such as more pronounced E
cycles and global warming.  Furtherm
agricultural practices, poor surveillance, prevention and control of vector borne-disease 
In Nigeria, it is very clear to all healthcare professionals that a major source of 
substandard products in Nigeria is the multitude of unregulated drug markets in major cities. 
These markets have existed since the 60’s and have grown in number and complexity over the 
years. They have survived the efforts of various Nigerian governments to forcefully dismantle 
them, which never succeeded (28).  With previously failed regulation techniques and seemingly 
uncontrollable distribution channels, the National Agency for Food, Drug, Administration & 
Control (NAFDC) was created to intervene on present markets, and decide on a new approach.   
The establishment of NAFDAC by Decree 15 of 1993 regulates and controls the manufacture, 
importation, exportation, distribution, advertisement, sale and use of food, drugs, cosmetics, 
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 brand, and then 
if they n fact 
 
ry 
 
atment 
ntinue to linger amidst patients who receive genuine 
medical devices, chemicals and packaged water (28). The difficulty of policing antimalarial 
counterfeit production as well as adherence, we must note some factors that are unique to 
Nigeria, and others that are not. “The ones that are common are just pure resistance to change, 
and inertia of habit,” said one public health official we interviewed.  Those that are unique are 
the influence of high degree of corruption and lack of accountability.  Public officials often have 
high significance but with divested interest between their private and public enterprise duties 
versus their public service and public safety. There was significant opposition to NAFDAC, so 
much so that the head of NAFDAC, Dr.Akunyili had numerous assassination attempts on her 
life. Following these death threats, there were arson fires at the operational laboratory 
headquarters of NAFDAC in Lagos, and Kaduna.  Nonetheless, Nigeria faces further concerns 
with misleading advertisements.  For example, there might be ten or more varieties of 
chloroquine on the market, all marketed as malaria therapies under different brand names (28). In 
reality, many of these drugs are the same thing, but since being advertised as different drugs the 
general public were left confused. “If they had malaria they would often buy one
didn't improve buy another brand, and so on, without understanding that they were i
buying the same pharmaceutical substance,” says Dr.Akunyili of NAFDC (24).  
As many have pointed out, the health cost of counterfeit drugs on the population of 
Nigerian citizens has jeopardized the reputation of the public health system; including health
care professionals, pharmaceutical industries, hospitals and clinics, and national Drug Regulato
Authorities (DRA’s).  Cases of antimalarial drugs containing no active ingredients, or with
wrong ingredients or without correct quantities of the active ingredient, prolong the tre
periods, which can lead to the emergence of resistant organisms. It is no wonder then that 
concerns over trust and safety co
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antimal
o
treatment failures (32).  The importance of public education in 
rational drug use and proper adherence seems to be a critical aspect in antimalarial drug 
r 
iotic access are as follows:  
of locally manufactured food, drugs, cosmetics, medical devices, water, 
detergent and chemicals.  
arials, but may fail to respond due to resistance induced from consumption of reduced-
dose counterfeit antimalarials.  
Literature has also shown overwhelming concerns about adherence to drug regimens by 
patients, which directly influences antimalarial efficacy that could lead to drug resistance. 
Underuse through lack of access, inadequate d sing, poor adherence, and substandard anti-
microbials may play as important a role as overuse (27). Second tier antimalarial drugs, such as 
Artensunate, that require an expensive extraction process makes them too costly for developing 
countries is a problem, because the few patients who can afford them, often have difficulty 
complying with the course of treatment. Research has also shown that in some cases, a 
chloroquine injection, administered by ill-qualified patient medicine dealers contributes to 
antimalarial drug resistance.  Two aspects of drug abuse [are] observed here, i.e. the utilization 
of sub-curative doses of chloroquine and monotherapy are believed to be two of the factors that 
lead to the several chloroquine 
resistance. . 
 
NAFDAC operational guidelines:  
The decree setting up NAFDAC mandated it to regulate and control the importation, 
exportation, manufacture, advertisement, distribution, sale and use of drugs.  Some of its othe
functions to regulate general antib
• Registration 
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evices, water, detergent and 
• Issuance of Narcotics and Controlled Substances permit.  
• Registration of vaccines and biologicals.  
To enforce these regulatory practices, the NAFDAC proposed the concept of Zonal Drug 
Distribution Centers in the six Geo-political zones of Nigeria.   
 
Nigerian Government Antimalarial Drug Regulation  
his 
ness 
ve 
• Registration of imported food, drugs, cosmetics, medical d
chemicals.  
• Exportation of locally manufactured regulated products.  
• Importation of regulated products.  
 NAFDAC’s proposed concept of Zonal Drug Distribution Centers in the six Geo-
political zones of the country was meant to centralize drug distribution across the country.  T
idea is similar to the combination drug market concept of India, Cameroon and the solely 
government-run retail pharmacy system of Sweden, the Apoteket AB. This is similar to the 
concept of Zonal Drug Distribution Centers (ZDDC) that was explored in the past but was 
abandoned due to funding constraints (28, 29).  Despite that initial setback, Dr. Akunyili’s fight 
against counterfeit unregulated products has produced rewarding results because of aware
campaigns and enforcement activities embarked upon by NAFDAC.  Since their inception, three 
special zonal offices [that were] established in the high incidence areas of distribution of 
faking/counterfeiting of regulated products Onitsha, Aba, and Kaduna in addition to Lagos, ha
assisted NAFDAC in confiscating and destroying fake drugs and other regulated products worth 
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e 
 
 bulletin 
fied 
 provisions of this Decree rests on the Federal Task Force on Counterfeit and Fake 
Drugs, hitherto a unit under the office of the Dire
limited to:   
1)-Coordinating the state Task Forces by the Federal Task Force as provided by the Law. 
2)-Tracking down the increasing perverseness of spurious products fakers and importers. 
several billions of Naira (29).  These drugs are concealed in men’s, women’s, and children’s 
clothing, duvets, and shoes (see figure 5).  NAFDAC’s bid to rid the country of fake, adulterated,
substandard drugs lies solely on distinguishing features between their genuine products and fak
ones.  Workshops held with various stakeholders dwelt on the dangers of fake drugs, resulted in 
billboards being erected in strategic parts of the country warning against the health hazards of 
fake drugs and other substandard products have also been produced and circulated nation-wide.
The Agency also publishes a Bi-annual NAFDAC News magazine and consumers safety
(29).    Identifying these salient gaps is enforced by the directorate for necessary action toward 
importers and manufacturers of unregistered products spurred by publications to initiate 
registration of their products due to the negative publicity and reduction in sales they get from 
the publication (29).  NAFDAC also engages in periodic publication of blacklisted companies, 
both local and international, who do not conform to World Health Organization (WHO) certi
Good Manufacturing Practice (GMP) or produces substandard products, to warn importers and 
consumers so as to shun products from these companies (29).  The overall responsibility for 
enforcing the
ctor – General.  Their duties include but are not 
3)-Coping with increasing sophistication of the criminals involved in faking products. 
20 
 
rting 
ke drugs into the country (29).  Similar sentiments were felt by drug companies who were 
arful that their brands would be rejected if news of fake drugs was broken to the media. Other 
third world countries like Mali have also experimented with other relevant drug initiatives. 
 
 
Lastly, the Director-General also held top level meetings with the managing director of Federal 
Airport Authority of Nigeria (FAAN) and Airline officials over the airlifting of fake drugs and 
substandard regulated products by Ethiopian Airline, KLM and other courier companies.  A 
major fall-out of the meeting was the new standing policy that any airline carrying fake regulated 
products will be prosecuted by NAFDAC apart from having their aircrafts grounded. This is a 
practical approach towards tackling the latest dimension of using airports as route for impo
fa
fe
 
Figure 5: Fake drug concealment.  Source: NAFDAC 
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se 
 of 
 
affordable drugs to meet their health care needs.  This scheme was adopted to overcome the 
budgetary allocation from government and high drug prices that involves a competitive tendering 
process where retail prices are set in such a way as to recover cost with a profit margin of ׽5%. 
majority of users of public health facilities either belong to the low-or middle-income 
roups, huge price differentials between ACMs and the older classes of antimalarials plays a 
ctor in mortality and morbidity (33), just as the Obala Foundation initiative or experiment 
veals.   
Bamako Initiative 
 
  In 1987 in Bamako, Mali, an initiative was taken and adopted by African health 
ministers to implement strategies designed to establish realistic national drug policies to increase 
the availability of essential drugs and other healthcare services for Sub-Saharan Africa.  The
observations could indicate that the availability of ACMs is probably sustainable on the basis
the Drug Revolving Fund (DRF) scheme, which is a drug supply management strategy to ensure
that the majority of service users have access to a sustainable supply of safe, effective, and 
inability of public health facilities to meet their drug demands that usually results from limited 
Prices are fixed to make our drugs more competitive than are obtainable at our competitor 
private pharmacies (33).  This observation is [also] intriguing within the context of Nigeria, 
where the 
g
fa
re
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mes: health 
funding
 
 
 
 
Obala Foundation  
Obala Foundation is a non-profit organization based in the United States and Nigeria 
since 2001. The problem, as Obala Foundation perceives it, is an inefficient and sub-optimal use 
of both monetary and human health care resources to tackle antimalarial drug resistance, which 
impedes implementation of even the most well thought-out policies.  As its mission statement 
states, “its principal approach is to foster stakeholder partnerships that focus on improving health 
care access and optimizing use of current resources.  Obala Foundation would like to use proven 
cost-effective technical interventions and techniques that address among other the
 that goes towards drug resistance in the form of surveillance, control of antimalarial 
drug distribution through integrated health information services, and involving stakeholders in 
the process to overcome opposition to antimalarial drug policy changes in Nigeria.   
Obala’s vision to address these thematic problems requires a multi-step process that will 
allow identification of gaps and limiting factors that impede current policies.  Obala’s goal is to 
explore the lack of antimalarial drug regulation on malaria, and whether it would be beneficial to 
have policies that regulate antimalarial drugs.  There are two trains of thought Obala would like 
to explore.  First, is the case that antimalarial drug use should be solely on a prescription basis in 
order to reduce drug resistance, reduce rate of complication, and reduce the number of fake 
drugs.  In contrast, is the idea that regulating these antibiotics (i.e. antimalarials) solely on a 
23 
 
an behavior, climate 
hanges, poverty, access to healthcare, health care providers, and resentment against government 
 are determined in their efforts to pursue new ideas and bold projects that should 
enable Nigerian communities to live a better life, free from disease and suffering 
 
xperts 
 
ents to come to our own conclusions.  After each interview was conducted, we 
qualified and grouped each answer by the interviewee into themes.  Those interviewees that had 
 same question were then linked and summarized together in our analysis.  
 
prescription basis limits access, which the Bamako Initiative sought to prevent.  In short, if there 
was no regulation and things were kept the way they are now, the percentage of people you 
would be helping by allowing access to OTC drugs is more than the people you would be 
helping if you had regulation. Simply, because OTC drug access reduces cost barriers such as 
physician fees.  However, drug resistance to antimalarials is being caused by substandard dosing 
which is related to OTC drug use, when people do not take the medication correctly. 
Furthermore, distribution of access may also “increase inequity since they will initially reach 
those who are already better off (11), which means that public good distribution must also be 
considered.  Obala also understands that there are other confounding issues; economics, political 
unrest, lack of interest groups, staying power, corrupt government, hum
c
interference. Still, they
Expert Interviews:  
Our interview questions (Please refer to Appendix) sought the input of high level e
and officials whom we gathered their input by careful note taking, e-mail, and phone interviews. 
Based on these finding along with the literature review, we were able to surmise their thoughts 
and comm
similar answers to the
24 
 
onship between policy formation 
and imple
 
This will involve education at schools, workplaces, community-based clinics, hospitals, and 
greater prevention efforts from government officials to prevent counterfeit and substandard drugs 
 flooding the markets.  The results and recommendations are summarized below. 
Discussion/Results: 
Malaria, and the difficulty in controlling antimalarial drug resistance is determined by a 
variety of factors, each varying in degree of intensity, breadth, and scope as it relates to 
antimalarial resistance.  In all, these factors must and will evolve positively or negatively over 
the next few years to contribute to lessoning Nigeria’s antimalarial drug resistance problem:  
including, climate, ecology, personal behavior, and compliance with appropriation for safe 
antimalarial drug use as an eminent dilemma.  However, practical steps can be taken to push that 
day further into the future (13).  These practical steps should include bolstering the fragmented 
relationship of the government to the private sector, the distribution of authority and 
responsibility within a federal system of government, the relati
mentation, and using incrementalism as the strategy for reform and better public 
education campaigns as they relate to antimalarial resistance.  
The core recommendations from this literature review are built on fundamental principles 
of a human rights framework that acknowledge a community-patient focus. The framework is 
based on public health principles and disease management, with a strong emphasis on health 
promotion, and integration of resource utilization practices that can be incorporated across the 
continuum of care. A wide range of health-related disciplines must join forces if opportunities to 
reduce the morbidity and mortality associated with chronic disease are to be realized. Presently,
there is an opportunity to establish new guidelines for antimalarial drug resistance prevention.  
from
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an 
ly 
 
d 
e with this new one could help combat the rising tide of 
rug resistance in this neglected disease.”  However, it could be nearly 10 years before the drug 
 
re 
 
se benefits 
s, 
 
Climate & Ecology: The evolution of drug resistance is an inevitable consequence of genetics 
and natural selection when drugs are used against microbial pathogens, including the protozo
parasites that cause malaria. As effective and robust as the artemisinin drugs are today, it is on
a matter of time before genetically resistant strains emerge and spread.  There is some hope
however with emerging research as reported by Nature that shows promise in an antimalarial 
drug called acridone derivative, which is being developed by Jane Kelly and colleagues at 
Portland State University.  The drug “targets the way mosquitoes digest hemoglobin in red bloo
cells, from which they take amino acids as their food… a chemical which prevents the malaria 
parasite from getting rid of a toxic by-product of feeding on red blood cells.   Furthermore, “it 
also disables a genetic defense that prevents the existing drugs chloroquine and quinine [from] 
working, useful again by combining thos
d
is available to pharmaceutical markets. 
 
Education & Compliance: Over the years, there has been significant criticism of OTC drug
regulation in developing countries as it relates to resistance.   As one scientist says, “mo
education was needed knowing when to use an antibiotic is as important as knowing which 
antibiotic to choose” (26).  Citizens can buy OTC antimalarials, which must contribute
significantly to development of resistance. There are arguments in favor of keeping the current 
policy in place stemming from people who can’t afford the fees. As one virologist we 
interviewed noted, “there are benefits to having people buying OTC drugs.  One of tho
would be, if you consider all the barriers to health care that people face when buying OTC drug
26 
 
 we 
 culture of self 
rescribing and self diagnosis that may lead to misdiagnosis of people or late diagnosis of 
-
es are 
ve costs 
you avoid those cost barriers which include doctor’s fees visits, administrative costs, 
transportation expenses.”  But on the contrary, as a study that was conducted at the University 
Teaching Hospital in central Nigeria suggested affordability was less of a factor in the 
acceptability of ACMs as the preferred treatment of malaria.  Moreover, “on an individual basis 
this may makes sense, but on a population-wide basis this is very detrimental because of easy 
access to irrational drug use, and high resistance. Even when the policies have changed, and
have limited the effectiveness with efficacy in reaction with other drugs, introduce
p
incorrect symptom, which is the very thing that proponents are trying to avoid.”  
 
Cost Containment: Poverty in sub-Saharan Africa, although not the chief factor, stifles the 
ability of people to purchase artemisinins, which at a dollar or two per course are both 
inexpensive by U.S. or European standards and highly cost effective by any norm. But neither 
national governments nor consumers in most malaria-endemic countries can afford them in 
quantities that remotely approach the world’s current consumption of chloroquine, roughly 300
500 million courses of treatment per year.  Commitments from international funding agenci
substantially greater than the sums needed for an antimalarial drug subsidy but still modest in 
terms of their return on investment, which are therefore needed to advance malaria control 
overall (13).  A global subsidy near the top of the distribution chain will stabilize demand and 
create incentives for ACT production, resulting in lower prices (13).  Essentially, this will give 
the global community leverage to dissuade artemisinin manufacturers who wish to sell through 
the subsidized system from producing artemisinin monotherapy, minimize administrati
of applying the subsidy, minimize the incentives for counterfeit ACT production, and minimize 
27 
 
 and 
 
er 
lect, and 
-economic inequity that influences the distribution of 
bination therapies like these have been used in treating HIV/AIDS, 
ria drug 
 
es 
 short 
incentives for diversion and smuggling of ACTs (13).   The United States Agency for 
International Development (USAID) is one such agency that realizes “since improved health
education are key determinants of development in Nigeria, previously separate efforts in basic 
education and health care will be integrated into a new objective for improved social sector 
service delivery”(USAID).  Expanding access to [cost] effective treatment will be essential to 
gain ground against malaria and drug resistance drugs.  Furthermore, at least one million people
die each year from malaria, most of who could have been saved by adequate treatment. Merely 
substituting artemisinin combination therapies (ACTs) for chloroquine is not the whole answ
(13).  Without funding for effective treatment, malaria mortality could double over the next 10 to 
20 years and transmission will intensify (14).  Policy-makers [must] increasingly engage in 
explicit discussions of the links between malaria, poverty, and inequity to adequately ref
distribute the same pattern of socio
infection. (11)  Com
tuberculosis, as well as malaria.   
 
Policy Implementation & Government Oversight:  The primary purpose of any mala
policy is to ensure prompt, effective, and safe treatment of malaria (5).  What will be required 
from the government is a distribution of authority and responsibility that regulates the 
implementation and availability of effective drugs at the local level through better control efforts
that previously may have been suppressed by corruption and ineffective drugs (13).  Government 
policy programs should implement interventions that develop a network of checks and balanc
to safeguard the antimalarial drug distributors, suppliers, and product content. This is not a
term solution, but a steady long term approach that will require an investment toward safety 
28 
 
cal 
caling 
 
 systems 
M 
 
 logistics epidemiology (IOM). Lastly, constructive engagement of all interested 
gencies must occur in a regional approach to have an effective policy dealing with the present 
 
inine and 
 
networks, and sufficient credible processes.  To what extent these credible sources can be 
developed and mobilized for efficiency, will require selective expertise in ideological, politi
and economic policy.  In addition, monitoring and evaluation systems are critical when s
up to sustain control and monitor pharmacovigilance and quality assurance.  An aggressive
stance during these challenging times will take greater effort and heavier supervision of 
pharmaceutical drugs for malaria and their counterfeits.  Presumably, enacting a technical 
approach that has been shown to work in other countries will be required to meet the emerging 
needs of the population, and special interest agencies.  One such approach was the use of 
procurement and supply chain management systems (PSMs).  Effective and timely PSM
are critical in delivering interventions and providing real-time feedback to NMCPs and district 
health centers on the flow of interventions. PSM systems need to be optimized to avoid 
forecasting errors, treatment expiries and intervention stock-outs. Furthermore, effective PS
systems can aid quality assurance and quality control (34).  Development and implementation of
product access plans to ensure timely and effective delivery of new antimalarial drugs will 
require personal expertise in relevant areas, including regulatory affairs, marketing, distribution 
and supply chain
a
day challenges. 
 
Antimalarial Treatment: Scientifically, certain aspects of antimalarial drug mechanisms are not
yet fully understood. In the absence of vaccines, these two plant-based compounds (Qu
artemisinin) and their derivatives have been crucial in the control of malaria. The complexity of
the parasite mechanism coupled with progressive resistance to malarial drugs presents 
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e 
rial 
inate their routine use as 
monotherapies and to treat patients with uncomplicated malaria (the vast majority of cases) with 
artemisinin-based combination therapies (ACTs) instead.  See figure 6. 
researchers with numerous difficulties in the development of both effective vaccines and mor
powerful pharmaceuticals (14).  Biomedically, the artemisinins are the only first-line antimala
drugs appropriate for widespread use that still work against all chloroquine-resistant malaria 
parasites.  A combination of mefloquine and artesunate [derivative of artemisinins] is highly 
effective even against multi-drug resistant malaria (14).  However, if resistance to artemisinins is 
allowed to develop and spread before replacement drugs are at hand, malaria’s toll could rise 
even higher.  The key, therefore, to preserving the artemisinins is to elim
 
Figure 6: Malaria disease. Edge thickness reflects relative strength of relationship. 
 
ams 
 
 
Community Health Workers: Increasing the number of NAFDC trained personal, along with 
general community health workers are preventative techniques that when combined with 
standard quality antimalarials may prevent disease morbidity statistics, reduce transmission, and
prevent overall drug-resistance.  However, lack of sufficient human resources to run progr
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as, 
l 
 
. Other creative approaches to expanding the workforce should be 
onsidered, such as using community health workers, volunteer networks or professionals in the 
 
 
hriveling of already limited 
humanitarian aid to fight dise
l 
e 
t decisively and imaginatively if we are 
and factors such as high attrition rates of skilled staff, difficulty filling positions in rural are
and competing demands with other programs directly influence control measures against 
antimalarial drug resistance.  Better incentives to retain professionals, especially technica
experts such as entomologists and public health workers are imperative to successful antimalarial
intervention coverage
c
private sector (34).   
Conclusion 
In summary, a great deal of work must be done to have access to a sustainable supply of 
safe, effective, and affordable drugs to meet the health care needs of an ailing Nigerian 
population.  The fear with the current financial and economic crisis facing the United States, and
much of the world, is that it is likely that we will witness a s
ases in developing countries. Without such funding, the challenge 
of arriving at a different conclusion is merely speculative.   
Public health policy care and reform in Nigeria will demand much from its champions.  
They will have to rebuild institutions which have lost the public trust and these champions wil
have to win support from the communities they hope to serve.  What must be expected from th
government is to use its complete power to prevent extreme inequality in health - not only by 
expanding healthcare access, but also by imposing containment costs and prioritizing quality 
measures that lead to improvements for all. We must ac
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to be faithful to George B. Shaw’s inspiring vision: “You see things; and you say, 'Why?' But I 
ream things that never were; and I say, "Why not?"   
 
 
 
 
 
ined 
a annua) or made synthetically. 
pecially for the 
ilability 
in or on the human body for the prevention 
 traditional medicines and biologicals including blood and 
n parasites (genus Plasmodium) in the red 
 by the bite of anopheles mosquitoes, and is characterized by periodic 
: Is a term that is recognized worldwide for the control and 
d
Appendix: 
 
 
Definition of Terms:  
Artemisinin: An antimalarial drug that is a peroxide derivative of sesquiterpene and is obta
from the leaves of a Chinese artemisia (Artemisi
Chloroquine: Drug used in the treatment or prevention of malaria. 
Mefloquine: An antimalarial drug similar to quinine that is administered es
prevention and treatment of falciparum malaria 
Bamako Initiative: In 1987 in Bamako, Mali, a formal statement initiative was taken and 
adopted by African health ministers to implement strategies designed to increase the ava
of essential drugs and other healthcare services for Sub-Saharan Africans. 
Drug (Medicine): A pharmaceutical product, used 
(prophylaxis), mitigation, diagnosis and/or treatment of disease, or for the modification of 
physiological function. This definition includes prescribed medicines, over-the-counter 
medicines, vaccines, herbal medicines,
blood-related products e.g. sera, plasma (28). 
Malaria: a human disease that is caused by sporozoa
blood cells, is transmitted
attacks of chills and fever (m-w.com) 
Naira:  Monetary unit of Nigerian currency. 
OTC: Over the counter 
Good Manufacturing Practice
management of manufacturing and quality control testing of foods, pharmaceutical products, and 
medical devices 
Interview Questions (25) 
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Nigeria?  
rug supply. Even if you succeed in establishing a stable supply of rationally 
y? In 
ited 
tries have 
 a national drug policy, in many cases, 
fessional groups who have had very little contact with each other 
hose people together to interact and communicate is a strengthening 
te of Medicine 
sidar): Used for treatment of uncomplicated Plasmodium 
lciparum malaria Synergistic action against susceptible attacks the different development stages of 
e parasite. 
HO: World Health Organization 
 
1. In some other countries that have made radical changes in drug policy, there has been 
considerable organized opposition, for example from industry and also from professional
groups, to the new legislation. Did that happen in 
2. May I ask you about the formal linkage between the decree and the national drug policy 
document that was published? This is a very comprehensive document covering every 
single aspect of pharmaceutical supply and use, so presumably some of the goals in this 
document are long term rather than short term?   
3. One aspect that is particularly interesting in the policy document is the emphasis on the 
importance of public education in rational drug use, because this is the vital final link in 
the chain of d
prescribed drugs, if the general public and patients don't understand how to use them, put 
pressure on health professionals for inappropriate therapies or modes of administration, 
or go and buy OTC products in a completely irrational way, then all the previous work is 
for nothing.  
4. Could we now turn to the development process of the Nigerian National Drug Polic
some countries, Malawi is an example, all interested parties involved with the supply and 
use of drugs: industry, the pharmacists, the medical profession, lawyers, etc, were inv
to participate in the development of the national drug policy. Other coun
adopted a somewhat different approach, and policy/legislation has been developed 
primarily within the government and with more limited participation from other interests, 
because those countries felt that the pressure of different interests might weaken the 
eventual legislation. How would you describe the Nigerian approach?   
5. We have found that the very process of developing
has brought together pro
before, and bringing t
process in itself. With that, how do you see the future development of Nigeria's 
pharmaceutical policy and sustainability efforts?   
IOM: Institu
Sulphadoxine-Pyramthenine (Fan
fa
th
W
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